Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Mar 23;312(7033):742-4.
doi: 10.1136/bmj.312.7033.742.

Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology

Affiliations

Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology

K F Schulz et al. BMJ. .

Abstract

Objective: To assess the methodological quality of approaches to blind ing and to handling of exclusions as reported in randomised trials from one medical specialty.

Design: Survey of published, parallel group randomised controlled trials.

Data sources: A random sample of 110 reports in which allocation was described as randomised from 1990 and 1991 volumes of four journals of obstetrics and gynaecology.

Main outcome measures: The adequacy of the descriptions of double blinding and exclusions after randomisation.

Results: Through 31 trials reported being double blind, about twice as many could have been. Of the 31 trials only eight (26%) provided information on the protection of the allocation schedule and only five (16%) provided some written assurance of successful implementation of double blinding. Of 38 trials in which the authors provided sufficient information for readers to infer that no exclusions after randomisation had occurred, six (16%) reported adequate allocation concealment and none stated that an intention to treat analysis had been performed. That compared with 14 (27%) and six (12%), respectively, for the 52 trials that reported exclusions.

Conclusions: Investigators could have double blinded more often. When they did double blind, they reported poorly and rarely evaluated it. Paradoxically, trials that reported exclusions seemed generally of a higher methodological standard than those that had no apparent exclusions. Exclusions from analysis may have been made in some of the trials in which no exclusions were reported. Editors and readers of reports of randomised trials should understand that flawed reporting of exclusions may often provide a misleading impression of the quality of the trial.

PubMed Disclaimer

References

    1. JAMA. 1975 Mar 10;231(10):1038-42 - PubMed
    1. JAMA. 1995 Feb 1;273(5):408-12 - PubMed
    1. Control Clin Trials. 1981 May;2(1):31-49 - PubMed
    1. N Engl J Med. 1982 Jun 3;306(22):1332-7 - PubMed
    1. Stat Med. 1983 Apr-Jun;2(2):155-66 - PubMed